LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

Publication | Closed Access

DOI

Citations

References

2020

Year

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Katina Robison, Johanna Mäenpää, Lyndsay Willmott,

Annals of Oncology

Hematological MalignancyLba31 Primary ResultsMedicineGynecologyImagyn050/gog 3015/Engot-ov39Immune Checkpoint InhibitorPharmacotherapyDouble-blind PlaceboCancer TreatmentOncologyRadiation OncologyGynecology OncologyOvarian Cancer